Bristol-Myers moves forward with its $1.2B CytomX alliance

Damian Garde

Bristol-Myers Squibb, working alongside Therapeutics, picked a third cancer project in a collaboration that could pay its partner as much as $ 1.2 billion.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS